Tag: endpoint

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1Pivotal Phase 3 CYPRESS study enrollment on track to complete by late...

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10...

Myra Vision Secures FDA Approval to Initiate US IDE Study in Glaucoma

The ADAPT study will evaluate the safety and effectiveness of the company's Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System CAMPBELL, Calif., Aug. 12, 2025 /PRNewswire/...

Netskope Recognized for Continued Leadership in Both SASE and SSE

Recent enhancements to Netskope One SASE help organizations from midmarket to large enterprise modernize for the cloud and AI era SANTA CLARA, Calif., Aug. 12,...

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Bragar Eagel & Squire, P.C. Reminds Investors of Class Actions Against Neogen, Alto, RxSight, and Replimune and Encourages Investors to Contact the Firm

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Neogen Corporation (NASDAQ:NEOG), Alto Neuroscience, Inc. (NYSE:ANRO), RxSight, Inc. (NASDAQ:RXST), and Replimune Group, Inc. (NASDAQ:REPL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed...

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in...

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR

ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Aug. 10, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. – ALT

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant –

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended June 30, 2025.

Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

- Halneuron^® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track as projected for Q4 2025 -

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsEndpoint

Rally House Ready with New York Knicks Championship Gear Following NBA Finals Victory

Marler Clark Urges Parents to Stop Using Nara Organics Whole Milk Organic Powdered Infant Formula Amid Multistate Infant Botulism Outbreak — Product Sold Nationwide...

First-Ever Edie Harper Tile Collection Debuts at Motawi Tileworks

Tag: endpoint

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Myra Vision Secures FDA Approval to Initiate US IDE Study in Glaucoma

Netskope Recognized for Continued Leadership in Both SASE and SSE

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Bragar Eagel & Squire, P.C. Reminds Investors of Class Actions Against Neogen, Alto, RxSight, and Replimune and Encourages Investors to Contact the Firm

Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. – ALT

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us